Skip to main content
MEDS
NASDAQ Trade & Services

DataMeds AI Reports $26.1M Loss, Going Concern Doubt, and Nasdaq Equity Deficiency

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Negative
Importance info
9
Price
$1.5
Mkt Cap
$4.179M
52W Low
$1.255
52W High
$97.5
52W Position info
20% above low
Off High info
98% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

MEDS sits 20% above its 52-week low of $1.255 on light trading volume (0.1× avg).

Summary

DataMeds AI's Q2 2026 report shows a $26.1M loss, going concern doubt, and a Nasdaq delisting risk due to stockholders' equity deficiency.


Key Events · Earnings and Guidance · MEDS

  • Going Concern Doubt

    Management states substantial doubt about the company's ability to continue as a going concern within twelve months, citing a $26.1M net loss, $137.1M accumulated deficit, and $19.5M stockholders' deficit.

  • Nasdaq Delisting Risk

    Nasdaq granted an extension until October 12, 2026 to evidence compliance with the minimum stockholders' equity requirement of $2.5 million. Failure to comply by the 2026 Form 10-K filing could lead to delisting.

  • Material Weaknesses

    Disclosure controls and procedures were not effective as of June 30, 2026 due to material weaknesses in internal control over financial reporting, including lack of documented policies and limited accounting personnel.

  • Loss on Debt Extinguishment

    Recognized an $8.88 million loss on extinguishment of debt from the May 2026 refinancing of convertible notes, contributing to the $18.4 million net loss for Q2 2026.


Analysis · MEDS · Trade & Services

The 10-Q reveals severe financial distress: a $26.1 million net loss for the first half of 2026, a working capital deficit of $33.8 million, and only $2.46 million in cash. Management states substantial doubt about the company's ability to continue as a going concern. Nasdaq has granted an extension until October 12, 2026 to regain compliance with the minimum stockholders' equity requirement, or the stock faces delisting. The company also disclosed material weaknesses in internal controls. These are critical risk factors that fundamentally alter the investment thesis.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MEDS was trading at $1.50 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $1.26 to $97.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MEDS - Latest Insights

MEDS
Nov 16, 2026, 8:42 AM EST
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.7001
Real-time Price: $0.6232 info
Change: -$0.0769 (-11%) info
Market Cap: $2.884M info
MEDS
Nov 16, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.710
Real-time Price: $0.6232 info
Change: -$0.0868 (-12%) info
Market Cap: $2.884M info
MEDS
Nov 13, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.7251
Real-time Price: $0.6232 info
Change: -$0.1019 (-14%) info
Market Cap: $2.884M info
MEDS
Nov 13, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7499
Real-time Price: $0.6232 info
Change: -$0.1267 (-17%) info
Market Cap: $2.884M info
MEDS
Nov 13, 2026, 10:20 AM EST
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $0.8795
Real-time Price: $0.6232 info
Change: -$0.2563 (-29%) info
Market Cap: $2.884M info